Barbara Duncan

Ms. Barbara G.
Duncan is an Independent Director at Halozyme Therapeutics, Inc., an Independent Director at Atea Pharmaceuticals, Inc. and an Independent Director at Ovid Therapeutics, Inc. She is on the Board of Directors at Halozyme Therapeutics, Inc., Halozyme, Inc., Versanis Bio, Inc., Atea Pharmaceuticals, Inc. and Ovid Therapeutics, Inc. Ms. Duncan was previously employed as a Chairman by Fusion Pharmaceuticals, Inc., an Independent Director by Immunomedics, Inc., an Independent Director by ObsEva SA, an Independent Non-Executive Director by Adaptimmune Therapeutics Plc, a Non-Executive Director by Adaptimmune Ltd., an Independent Director by Jounce Therapeutics, Inc., an Independent Director by Aevi Genomic Medicine, Inc., a Chief Financial Officer, Secretary & Treasurer by Intercept Pharmaceuticals, Inc., a Chief Executive & Financial Officer, Director by DOV Pharmaceutical, Inc., a Vice President-Corporate Finance Division by Lehman Brothers, Inc., a Director-Corporate Finance by SBC Warburg Dillon Read Corporate Finance AG, an International Auditor by PepsiCo, Inc., and a Senior Accountant by D&T Partners LLP.
She also served on the board at Innoviva, Inc. and Edgemont Pharmaceuticals LLC.
She received her undergraduate degree from Louisiana State University and an MBA from The Wharton School of the University of Pennsylvania.